Amplia Therapeutics Limited
Pharmaceuticals - North Melbourne, Victoria, Australia
Amplia Therapeutics Limited Employees
Amplia Therapeutics Limited Senior Management
Amplia Therapeutics Limited Details
Despite the recent success of immuno-oncology drugs, their use in fibrotic cancers (pancreatic, ovarian cancer) has been met with limited success. Recent research shows that Focal Adhesion Kinase (FAK) is significantly upregulated in these highly fibrotic tumours and therefore drugs targeting FAK have the potential to sensitize the tumour micro-environment to both I-O and chemotherapies. Inhibiting FAK can also directly boost the number of immune cells responsible for attacking tumours, further "amplifying" the effect of immuno-oncology treatment.Amplia Therapeutics Limited is a pharmaceutical company advancing a pipeline of FAK inhibitors for cancer and fibrosis. The lead molecule, AMP945, is a "pure play" inhibitor with superior specificity. The second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways – VEGFR3 and FLT3.
Amplia Therapeutics Limited Technologies
Email Providers
Outlook
Content Delivery Networks
Amazon CloudFront
Load Balancers
Amazon Elastic Load Balancer
Email Delivery
Mailchimp Mandrill
Other
Microsoft Office 365
Hosting
Amazon AWS